Nuvalent (NUVL)
NASDAQ:NUVL
Want to see NUVL full AI Analyst Report?
Top Page
Nuvalent
(NASDAQ:NUVL)
Select Model
Select Model
Rating:58Neutral
Price Target:
$108.00
▲(0.36% Upside)
Action:ReiteratedDate:04/08/26
The score is mainly held back by weak financial performance driven by no revenue, widening losses, and rising cash burn, despite a strong, debt-free balance sheet. Technicals are moderately positive with the stock trading above major moving averages and supportive momentum. Valuation is less favorable due to negative earnings (negative P/E), while the recent FDA NDA filing provides a constructive catalyst.
Positive Factors
Debt-free balance sheet
Zero reported debt and roughly $1.25B of equity provide durable financial flexibility to fund multi-year clinical programs, absorb R&D expense volatility, and reduce near-term refinancing risk. This low-leverage profile supports strategic optionality and runway for pipeline progress.
Negative Factors
No product revenue
Lack of product revenue means the company cannot organically fund operations; its economics rely entirely on capital markets or partnerships. Until commercial sales begin, sustainable profitability and operating leverage remain theoretical and contingent on successful approvals.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt and roughly $1.25B of equity provide durable financial flexibility to fund multi-year clinical programs, absorb R&D expense volatility, and reduce near-term refinancing risk. This low-leverage profile supports strategic optionality and runway for pipeline progress.
Read all positive factors
Nuvalent (NUVL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.51B
Dividend YieldN/A
Average Volume (3M)572.22K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS Growth-52.84%
CountryUS
Employees162
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.58
Shares Outstanding73,181,750
10 Day Avg. Volume531,449
30 Day Avg. Volume572,223
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-22.42
Forecast
1Y Price Target
$141.54Price Target Upside31.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-5.56
Revenue Forecast (FY)$13.81M
Nuvalent Business Overview & Revenue Model
Company Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinas...
How the Company Makes Money
Nuvalent is a clinical-stage company and, as of publicly available information up to my knowledge cutoff (2025-09), does not have approved commercial products. As a result, it does not generate recurring product sales revenue; its operations are p...
Nuvalent Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -10.48M | 0.00 | -126.22M | -86.11M | -45.82M |
| Net Income | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M |
Balance Sheet | |||||
| Total Assets | 1.41B | 1.14B | 732.38M | 482.46M | 293.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.37B | 1.12B | 719.90M | 472.16M | 288.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 164.37M | 71.96M | 31.82M | 19.48M | 8.79M |
| Stockholders Equity | 1.25B | 1.07B | 700.56M | 462.98M | 285.04M |
Cash Flow | |||||
| Free Cash Flow | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Operating Cash Flow | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Investing Cash Flow | -124.08M | -573.51M | -143.53M | -10.66M | -220.03M |
| Financing Cash Flow | 515.34M | 568.88M | 336.85M | 248.92M | 318.22M |
Nuvalent Technical Analysis
Positive
107.61
Price Trends
101.46
Positive
103.16
Positive
93.82
Positive
Market Momentum
1.41
Negative
62.44
Neutral
69.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUVL, the sentiment is Positive. The current price of 107.61 is above the 20-day moving average (MA) of 101.68, above the 50-day MA of 101.46, and above the 200-day MA of 93.82, indicating a bullish trend. The MACD of 1.41 indicates Negative momentum. The RSI at 62.44 is Neutral, neither overbought nor oversold. The STOCH value of 69.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUVL.
Nuvalent Risk Analysis
Nuvalent disclosed 90 risk factors in its most recent earnings report. Nuvalent reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuvalent Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $5.90B | 9.62 | 101.12% | ― | 100.88% | ― | |
58 Neutral | $8.51B | -17.19 | -42.07% | ― | ― | -52.84% | |
54 Neutral | $244.74M | -3.29 | -32.44% | ― | 106.27% | -43.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $8.15B | -9.72 | 172.91% | ― | 2609.26% | -17.08% | |
49 Neutral | $9.65B | -49.60 | -254.14% | ― | 65.83% | 28.50% |
* Healthcare Sector Average
NUVL
Nuvalent
107.13
35.74
50.06%
CYTK
Cytokinetics
65.80
27.99
74.03%
TGTX
TG Therapeutics
36.28
-1.71
-4.50%
AXSM
Axsome Therapeutics
182.97
79.15
76.24%
RNA
Atrium Therapeutics, Inc.
13.53
-1.22
-8.27%
Nuvalent Corporate Events
Product-Related AnnouncementsRegulatory Filings and Compliance
Nuvalent Files FDA Application for Lung Cancer Therapy
Positive
Apr 7, 2026
On April 7, 2026, Nuvalent, Inc. reported that it had submitted a New Drug Application to the U.S. Food and Drug Administration for neladalkib, a treatment candidate for patients with tyrosine kinase inhibitor pre-treated advanced ALK-positive non...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.